Why did Novo Nordisk stock drop today?

Shares fell after the company guided 2026 sales and operating profit down 5-13%, citing US pricing pressure and loss of exclusivity for semaglutide in China, Brazil and Canada. The ADS traded near $50, down about 15%, as investors reset expectations for revenue growth and margins given competitive and reimbursement headwinds in obesity and diabetes.

What should UK investors focus on next?

Watch management’s pricing and access commentary, timelines for oral obesity launches, dose availability, and capacity expansion. Track ex-US loss of exclusivity impact and any European pricing updates. Technically, monitor closes around the 50-day and 200-day moving averages. Consider currency exposure in GBP portfolios and position sizing given higher volatility.

How does Eli Lilly rivalry affect the outlook?

Competition intensifies on efficacy, tolerability and supply, which supports adoption but pressures pricing. Payors may tighten coverage and push for steeper rebates. This rivalry can weigh on gross-to-net in the United States, while driving faster innovation. The net effect depends on access wins, clinical differentiation and the pace of supply scaling in 2026.

Is the valuation now attractive after the drop?

At roughly 13-14 times earnings with strong profitability metrics, valuation is more reasonable than at recent peaks. The case hinges on net pricing resilience, successful oral launches, and controlled LOE erosion ex-US. For new positions, consider staged entries and clear risk limits, given uncertain 2026 growth and elevated day-to-day volatility.

Global Market Insights

NVO Stock Today: February 4 — Guides 2026 Sales/Profit Down 5–13%, Shares Sink

ByDanny Kontos February 4, 2026February 4, 2026

Novo Nordisk stock fell sharply today after management guided 2026 sales and operating profit down 5-13%, citing US pricing pressure and loss of exclusivity for semaglutide in China, Brazil and Canada. The US ADS, NVO, traded at $50.30, down 14.6% intraday. UK investors are weighing near-term margin pressure against potential upside from a US oral Wegovy launch and higher-dose rollouts in 2026. The company reports today at 13:30 GMT, and management commentary on pricing, capacity and payor access will be critical.